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Background. There is a paucity of information regarding the
clinical experience of Asian hemodialysis patients. This paper
describes intermediate outcomes for adult Asian hemodialysis
patients compared to Caucasians and African Americans.
Methods. Dialysis facility staff abstracted clinical informa-
tion on a national random sample of adult hemodialysis patients
from October through December 2000. Associations of race
with intermediate outcomes were tested by bivariate analyses
and multivariable logistic regression modeling.
Results. A total of 429 patients were identified as Asian, 4403
as Caucasians, and 3103 as African Americans. Asian and Cau-
casian patients were older than African Americans [mean 63.2
(15.6), 63.9 (15.2), and 57.7 (14.7) years, P  0.001], and
had fewer years on dialysis [mean 3.5 (3.8), 3.1 (3.8), and
4.1 (4.1) years, P  0.001]. Ninety three percent of Asians,
87% of Caucasians, and 84% of African Americans had a mean
Kt/V 1.2 (P  0.001). In addition, 36% of Asians, 32% of
Caucasians, and 26% of African Americans had an arteriove-
nous (AV) fistula as their vascular access (P  0.001). Hemo-
globin profiles were only slightly different among the three
racial groups. More Asians and African Americans had a mean
serum albumin 4.0/3.7 g/dL compared to Caucasians (33%
and 31% compared to 27%, respectively, P  0.001). In the
final multivariable logistic regression model, Asians were twice
as likely to have a mean Kt/V 1.2 compared to Caucasians
(the referent group) [odds ratio (OR) (95% CI) 2.10 (1.33,
3.32), P  0.01]. They experienced similar intermediate out-
comes for vascular access, anemia management, and serum
albumin compared to the majority racial group.
Conclusion. These findings indicate that adult hemodialysis
Asian patients experience similar or better intermediate out-
comes compared to the majority racial group. Further study is
needed to determine if these results are associated with improved
survival and less morbidity in this minority group.
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In an effort to assist providers of end-stage renal dis-
ease (ESRD) services in the assessment of care provided
to ESRD patients and to stimulate improvement in that
care [1, 2], the Centers for Medicare & Medicaid Services
(CMS’s) ESRD Clinical Performance Measures (CPM)
Project annually profiles certain intermediate outcomes
of care for nationally representative samples of adult
(18 years) in-center hemodialysis and adult peritoneal
dialysis patients in the United States. Previous analyses
have demonstrated differences in dialysis practices and
intermediate outcomes for African Americans and His-
panics, as compared to the Caucasian adult hemodialysis
population [3]. For instance, compared to Caucasians,
African Americans were less likely to have an arteriove-
nous (AV) fistula and were more likely to have a deliv-
ered Kt/V 1.2, whereas both Hispanics and African
Americans were more likely to have a mean serum albu-
min4.0/3.7 g/dL [bromcresol green (BCG)/bromcresol
purple (BCP) laboratory methods] [3]. This study focuses
on intermediate outcomes in the adult Asian-American
dialysis population.
The Asian American population is one of the fastest
growing minority groups in the United States. [4] This
racial group has been reported to have an increased risk
of developing ESRD as compared to Caucasians. [5] In
addition, Asian hemodialysis patients, in general, and
Asian American patients, in particular, have been re-
ported to have a 25% to 35% lower mortality rate as com-
pared to their Caucasian counterparts [6, 7]. Whether
or not these differences in survival rates can be ac-
counted for by differences in dialysis practices is unclear.
Identification of favorable dialysis treatment practices
in this subgroup may have potential implications in the
approach to treatment in other racial subgroups.
In order to examine whether dissimilarities exist in
dialysis treatment practices and intermediate outcomes
in the Asian population, an oversampling of adult in-
center hemodialysis Asian patients was performed for
the 2001 data collection. Intermediate outcomes in the
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following areas were measured: adequacy of hemodialy-
sis, anemia management, vascular access, and serum al-
bumin. This report will describe the findings for adult
hemodialysis Asian patients compared to Caucasian and
African American patients in the sample.
METHODS
Study design and sample selection
Detailed information about CMS’s ESRD CPM Proj-
ect has previously been published [3]. In brief, in March
2001, a listing of patients who were alive and receiving in-
center hemodialysis on December 31, 2000 was obtained
from the 18 ESRD Network organizations (regional or-
ganizations contracted by CMS to perform quality over-
sight activities to ensure the appropriateness of services
and protection for dialysis patients). Patients were eligi-
ble for inclusion in the sample if they were at least 18
years old as of October 1, 2000. A national random
sample, stratified by the 18 ESRD Networks, was drawn.
An additional number of adult Asian hemodialysis pa-
tients was then drawn (the oversample) so that a total
of 500 adult Asian patients were sampled. The ESRD
Core Indicators/CPM Projects had previously deter-
mined that a sample size of at least 400 was needed to
provide statistically stable estimates, so 500 patients were
sampled to account for some nonresponse. Clinical infor-
mation was obtained on the selected patients for October
through December 2000.
Data collection
In May 2001, the ESRD Networks sent a three-page
data collection form to all facilities with one or more
patients selected for the sample. Available patient infor-
mation included gender, age, race (Caucasian, African
American, Asian, Pacific Islander, Mid-East Arabian,
Indian Subcontinent, American Indian/Alaska Native,
Other Multiracial, and unknown), Hispanic ethnicity, the
primary cause of ESRD, and years on dialysis therapy.
Patient data were abstracted from medical records by
the dialysis facility staff for each month of the study period
and included the patient’s height, first documented pre-
and postdialysis blood urea nitrogen concentration (BUN)
and pre- and postdialysis patient weights, delivered dial-
ysis session length, dialyzer code [used to determine dia-
lyzer KUf, (ultrafiltration coefficient, a measure of fluid
removal)], blood pump flow rate 60 minutes during the
session the BUNs were drawn, type of vascular access,
hemoglobin, prescribed weekly erythropoietin dose at the
time the hemoglobin was drawn and route of administra-
tion, transferrin saturation, serum ferritin concentration,
iron prescription practice, and serum albumin with the
laboratory method used to determine the serum albumin,
as the two commonly used methods (BCG/BCP) have
been reported to yield systematically different results [8].
Completed forms were returned to the appropriate
ESRD Network office where data were reviewed and
entered into a computerized database [9]. The data were
forwarded to CMS for aggregation and analysis.
Data analysis
To be included in the sample for analysis, a patient
had to have data for at least one of the study months
for paired pre- and postdialysis BUN values, hemoglo-
bin, and serum albumin reported on the data collection
form. Racial analysis was restricted to Asian, Caucasian,
and African American groups due to the small numbers
in other racial groups. Erythropoietin sensitivity was cal-
culated according to the method described by Kim et al
and expressed as weekly erythropoietin dose/hemoglo-
bin/body weight in kilograms [10]. Associations of group
classification with the clinical data were tested by chi-
square, two-tailed Student t test and hierarchical analysis
of variance (ANOVA) analyses. A two-tailed P value 
0.05 was considered to be significant.
Multivariable logistic regression analyses were per-
formed separately for the following dependent variables:
achieving a mean Kt/V 1.2, a mean hemoglobin 11
g/dL, use of an AV fistula, and a mean serum albumin
4.0/3.7 g/dL (BCG/BCP). Variables entered into the
initial adjusted model included race (Asian, Caucasian,
or African American), gender, age, diabetes mellitus as
the cause of ESRD compared to other causes combined,
years on dialysis (less than 0.5 years, 0.5 to 0.9 years, 1.0
to 1.9 years, and 2 or more years—the referent category),
quartile of postdialysis body mass index (BMI), type of
vascular access (AV fistula or AV graft compared to the
referent, catheter), mean dialysis session length, mean
blood pump flow, mean Kt/V, mean hemoglobin, mean
serum albumin, and ESRD Network. The Network ranked
9th for each intermediate outcome was the referent Net-
work in the model developed for each intermediate out-
come. Both forward stepwise and backward stepwise
modeling techniques were employed, utilizing the likeli-
hood ratio statistic. Due to the multiple comparisons
made, only predictors with a P value  0.01 were re-
tained in the final adjusted models predicting the differ-
ent intermediate outcomes.
The data analyses were conducted utilizing Epi Info
version 6.04a (Centers for Disease Control and Preven-
tion, Atlanta, GA, USA) and SPSS for Windows, version
10.0 (SPSS, Inc., Chicago, IL, USA) [11].
RESULTS
A total of 8853 patients were selected for the national
random sample. Two hundred and forty-five patients
in this national sample were identified as Asian. An
additional 255 Asian patients were randomly selected to
yield 500 Asian patients for the national sample. Of the
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Table 1. Selected patient characteristics, by race
Characteristic Asian N (%) Caucasian N (%) African American N (%)
Total 429 (100) 4403 (100) 3103 (100)
Gendera
Male 209 (49) 2406 (55) 1526 (49)
Female 220 (51) 1995 (45) 1576 (51)
Ethnicitya
Hispanic 11 (3) 797 (18) 41 (1)
Non-Hispanic 404 (94) 3399 (77) 2907 (94)
Age years
Mean (SD)a 63.2 (15.6) 63.9 (15.2) 57.7 (14.7)
Median 66.1 66.7 58.2
Age groupa
18–44 61 (14) 578 (13) 620 (20)
45–54 63 (15) 628 (14) 697 (23)
55–64 78 (18) 812 (18) 742 (24)
65–74 117 (27) 1167 (27) 663 (21)
75 110 (26) 1218 (28) 381 (12)
Postdialysis body mass index kg/m2
Mean (SD)a 23.0 (4.7) 26.4 (6.3) 27.2 (7.3)
Median 22.4 25.3 25.8
Primary cause of end-stage renal diseasea
Diabetes mellitus 175 (41) 1831 (42) 1192 (38)
Hypertension 121 (28) 839 (19) 1140 (37)
Glomerulonephritis 47 (11) 551 (13) 329 (11)
Other/unknown 86 (20) 1182 (27) 442 (14)
Duration of dialysis years
Mean (SD)a 3.5 (3.8) 3.1 (3.8) 4.1 (4.1)
Median 2.1 1.9 2.9
Duration of dialysis groupa
0.5 43 (10) 629 (14) 273 (9)
0.5–0.9 60 (14) 681 (16) 341 (11)
1.0–1.9 92 (22) 988 (23) 545 (18)
2.0 231 (54) 2085 (48) 1907 (62)
Subtotals may not add up to 429 (Asian), 4403 (Caucasian) or 3103 (African American) due to missing data. Percentages may not add up to 100% due to rounding.
aP  0.001 notes significant differences by race
9108 patients 8613 patients (95%) met the criteria for
inclusion in the sample for analysis. The sample for anal-
ysis included 429 (5%) Asian, 4403 (51%) Caucasians,
and 3103 (36%) African American patients. Asian pa-
tients were more prevalent in California, the Pacific
Northwest, and New York, accounting for 67% of the
Asians in the sample.
The Asian and African American groups had a smaller
percentage of males compared to Caucasians (49% com-
pared to 55%, P  0.001). (Table 1) Asians and Cauca-
sians were older than African Americans [mean 63.2
(15.6) and 63.9 (15.2) years compared to 57.7 (14.7)
years, respectively, P  0.001]. Forty-one percent of
Asian and 42% of Caucasian patients had diabetes melli-
tus as the primary cause of ESRD compared to 38% of
African American patients (P  0.001). Asians had an
intermediate duration of dialysis therapy compared to
Caucasians and African Americans [3.5 (3.8) years
compared to 3.1 (3.8) and 4.1 (4.1) years, respec-
tively, P 0.001]. Median (and 25th and 75th percentile)
values for duration of dialysis were 1.89 (0.85 and 3.84,
respectively) years for Caucasian patients, 2.11 (1.05 and
4.64, respectively) years for Asian patients, and 2.89 (1.26
and 5.56, respectively) years for African American pa-
tients. Asian patients were significantly smaller than
Caucasian and African American patients, with a mean
postdialysis BMI of 23.0 (4.7) kg/m2 compared to 26.4
(6.3) and 27.2 (7.3) kg/m2, respectively (P  0.001).
Adequacy of hemodialysis
Asian patients had a significantly higher mean Kt/V
compared to Caucasian and African American patients
[1.62 (0.30) compared to 1.50 (0.29) and 1.46 (0.28),
respectively, P  0.001], and a higher percentage had a
mean Kt/V 1.2 (93% compared to 87% and 84%, P 
0.001) (Table 2). Similar results were noted for hemodial-
ysis adequacy as measured by urea reduction ratio. Dial-
ysis session lengths were significantly shorter for Asian
patients compared to Caucasians and African Americans
[200 (29) minutes compared to 214 (30) and 220
(30) minutes, respectively, P  0.001]. There was no
difference in the use of high-flux dialyzers (KUf 20
mL/mm Hg/hour) among racial groups. Mean blood
pump flow rates were significantly slower for Asian pa-
tients compared to Caucasians and African Americans
[372 (62) mL/min compared to 386 (68) and 404
(71) mL/min, respectively, P  0.001].
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Table 2. Selected clinical measures of interest, by race
Clinical measurea Asian Caucasian African American
Adequacy of dialysis
Calculated Kt/V
Mean (SD)b 1.62 (0.30) 1.50 (0.29) 1.46 (0.28)
Median 1.62 1.50 1.46
Mean Kt/V  1.2b 93% 87% 84%
Calculated urea reduction ratio %
Mean (SD)b 73.7 (7.0) 71.0 (7.1) 69.7 (7.1)
Median 74.5 71.7 70.6
Mean urea reduction ratio  65%b 92% 84% 79%
Dialysis session length minutes
Mean (SD)b 199.5 (29.4) 213.6 (30.1) 219.6 (29.5)
Median 195 210 219.7
Dialyzed with a high-flux dialyzer
KUf  20 mL/mm Hg/hour 71% 71% 72%
Blood pump flow rate mL/minute
Mean (SD)b 372 (62) 386 (68) 404 (71)
Median 383 400 400
Vascular access
Type of accessc
Arteriovenous (AV) fistula (all patients)b 36% 32% 26%
AV fistula (incident patientsd) 33% 27% 26%
AV graftb 45% 41% 52%
Catheterb 19% 27% 22%
Catheter in use 90 daysb 13% 18% 15%
Anemia management
Hemoglobin g/dL
Mean (SD)e 11.7 (1.1) 11.7 (1.2) 11.6 (1.2)
Median 11.7 11.7 11.7
Mean  11 g/dL 75% 75% 73%
Mean 11.0–12.0 g/dLf 38% 38% 38%
Mean 11.0–12.9 g/dLf 66% 64% 64%
Mean  9 g/dLe 1.4% 2% 3%
Mean  10 g/dL 7% 8% 9%
Patients prescribed erythropoietinb 99% 95% 96%
Within this group
Intravenouse 89% 90% 92%
Subcutaneousg 11% 12% 9%
Erythropoietin dose units/kg/dose
Intravenous
Mean (SD)b 89.3 (75.8) 79.2 (68.5) 86.2 (73.8)
Median 69.1 60.8 65.7
Subcutaneous
Mean (SD) 84.3 (66.8) 65.9 (53.9) 68.3 (48.0)
Median 67.0 49.9 56.0
Erythropoietin sensitivity weekly dose/hemoglobin/kg
Intravenous
Mean (SD)g 24.0 (24.7) 21.3 (22.4) 23.2 (21.6)
Median 17.7 15.7 17.3
Subcutaneous
Mean (SD) 21.7 (18.3) 17.9 (16.2) 18.5 (14.0)
Median 17.3 13.1 14.8
Transferrin saturation %
Mean (SD)b 30.3 (12.8) 27.7 (12.5) 29.1 (12.9)
Median 28.0 25.7 26.7
Mean transferrin saturation 20%b 83% 75% 79%
Serum ferritin concentration ng/mL
Mean (SD)b 594 (426) 495 (380) 564 (403)
Median 529 428 496
Mean serum ferritin 100 ng/mLb 92% 88% 91%
Patients with relative iron deficiencyg,h 2% 5% 4%
Patients prescribed ironb 61% 70% 70%
Within this group
Intravenous 89% 92% 92%
Orally 18% 14% 15%
Serum albumin
Bromcresol green method (BCG)
Mean (SD)b 3.82 (0.38) 3.73 (0.39) 3.77 (0.38)
Median 3.87 3.77 3.80
(Continued )
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Table 2. (Continued)
Clinical measurea Asian Caucasian African American
Bromcresol purple method (BCP)
Mean (SD)b 3.43 (0.45) 3.47 (0.46) 3.63 (0.42)
Median 3.53 3.52 3.67
Mean serum albumin 4.0/3.7 g/dLb (BCG/BCP) 33% 27% 31%
Mean serum albumin 3.5/3.2 g/dLb (BCG/BCP) 82% 78% 83%
a Continuous variables are displayed as the mean (SD) and median values; categorical variables displayed as percent of available values
b P  0.001 notes significant differences between racial groups
c Vascular access used on last hemodialysis session during the study period
d An incident patient defined as initiating in-center hemodialysis on or between January 1, 2000 and August 31, 2000
e P  0.05 notes significant differences between racial groups
f Among patients prescribed erythropoietin
g P  0.01 notes significant differences between racial groups
h Relative iron deficiency is defined for this report as a mean transferrin saturation 20% and a mean serum ferritin concentration 100 ng/mL
Vascular access
A significantly greater percentage of prevalent Asian
patients, despite their smaller body size, were dialyzed
with an AV fistula compared to Caucasians and African
American patients (36% compared to 32% and 26%,
respectively, P  0.001) (Table 2). Among incident pa-
tients (those initiating dialysis on or between January 1,
2000 and August 31, 2000), 33% of Asians were dialyzed
with an AV fistula compared to 27% of Caucasians and
26% of African Americans (NS). The use of AV grafts
was intermediate for Asian patients in this sample (45%
compared to 41% for Caucasians and 52% for African
Americans, P  0.001). Catheter use was significantly
less for the Asian group, with 19% of Asian patients
dialyzed with a catheter compared to 27% of Caucasians
and 22% of African Americans (P  0.001). A similar
trend was noted for chronic catheter use (use of a cathe-
ter for 90 or more days) among the three racial groups.
Anemia management
Mean hemoglobin was slightly higher for Asian and
Caucasian patients compared to African American pa-
tients [11.7 (1.1) and 11.7 (1.2) g/dL for Asians and
Caucasians compared to 11.6 (1.2) g/dL for African
Americans, P  0.05) (Table 2). Similar percentages
of patients in the three racial groups attained different
thresholds for mean hemoglobin.
Ninety-nine percent of Asian patients were prescribed
erythropoietin, compared to 95% of Caucasians and 96%
of African Americans (P  0.001). The mean intrave-
nous erythropoietin dose was significantly higher for
Asian patients compared to Caucasians and African
Americans [89.3 (75.8) units/kg/dose compared to 79.2
(68.5) and 86.2 (73.8) units/kg/dose, P  0.001]. A
similar trend was noted for subcutaneous doses across
racial groups. Asians demonstrated a lower erythropoie-
tin sensitivity as suggested by the higher weekly median
dose of erythropoietin required per hemoglobin unit
compared to Caucasians and African Americans (intra-
venous 17.7 weekly dose/hemoglobin/kg compared to
15.7 and 17.3 weekly dose/hemoglobin/kg). A similar trend
was noted among patients prescribed subcutaneous
erythropoietin and across categories of iron status.
The mean transferrin saturation was significantly higher
for Asian and African American patients compared to
Caucasians [30.3% (12.8%) and 29.1% (12.9%) com-
pared to 27.7% (12.5%), respectively, P  0.001]. A
higher percentage of Asians had a mean serum transferrin
20% [83% compared to 75% (Caucasians) and 79%
(African Americans), P  0.001]. Similarly, mean serum
ferritin concentrations were higher for Asians compared
to Caucasians and African Americans [594 (426) ng/mL
compared to 495 (380) and 564 (403) ng/mL, respec-
tively, P  0.001]. Median (25th and 75th percentile)
serum ferritin concentrations were 428 (198 and 697, re-
spectively) ng/mL for Caucasians, 529 (248 and 842, respec-
tively) ng/mL for Asians, and 496 (248 and 796, respec-
tively) ng/mL for African Americans. A higher percentage
of Asians and African Americans had a mean serum ferri-
tin concentration 100 ng/mL compared to Caucasians
(92% and 91% compared to 88%, P  0.001). Only 2%
of Asian patients had relative iron deficiency (defined as
a mean transferrin saturation 20% and a mean serum
ferritin concentration 100 ng/mL) compared to 5% of
Caucasians and 4% of African Americans (P  0.01).
Sixty-one percent of Asian patients were prescribed
iron during the 3-month study period compared to 70%
of both Caucasian and African American patients (P 
0.001). Within the group of patients prescribed iron, no
significant differences in prescribed route of administra-
tion were noted across racial groups, with approximately
90% of patients in this subset prescribed intravenous iron.
Serum albumin
Asian patients had a higher mean serum albumin (BCG
method) compared to Caucasians and African Ameri-
cans [3.82 (0.38) g/dL compared to 3.73 (0.39) and
3.77 (0.38) g/dL, respectively, P  0.001] (Table 2).
A significantly higher percentage of Asian and African
American patients had a mean serum albumin 4.0/3.7
g/dL (BCG/BCP) compared to Caucasians (33% and
31% compared to 27%, respectively, P  0.001).
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Table 3. Multivariable logistic regression models for attaining selected intermediate outcomes
Mean serum
albumin
4.0/3.7 g/dL
Arteriovenous Mean hemoglobin (bromcresol green/
Mean KtV 1.2 fistula use 11 g/dL bromcresol purple)
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Predictor
Race
Asian 2.10 (1.33, 3.32)a 1.20 (0.94, 1.53) 1.05 (0.82, 1.34) NS
African American 0.49 (0.42, 0.58)b 0.64 (0.56, 0.72)b 0.86 (0.77, 0.96)a NS
Caucasian, referent
Male gender 0.17 (0.15, 0.21)b 1.99 (1.75, 2.26)b NS 1.85 (1.66, 2.06)b
Age years 1.023 (1.018, 1.029)b 0.982 (0.979, 0.986)b 1.010 (1.007, 1.014)b 0.977 (0.974, 0.981)b
Diabetes mellitus as cause of end-stage renal disease
(versus other causes combined) 0.70 (0.60, 0.82)b 0.74 (0.66, 0.82)b NS 0.61 (0.55, 0.68)b
Duration of dialysis years
0.5 0.32 (0.25, 0.39)b 0.68 (0.55, 0.84)b 0.49 (0.41, 0.57)b 0.45 (0.36, 0.55)b
0.5–0.9 0.59 (0.47, 0.74)b 1.10 (0.93, 1.29) 1.26 (1.06, 1.49)a 0.65 (0.55, 0.76)b
1.0–1.9 0.77 (0.63, 0.95)c 1.20 (1.04, 1.37)a 1.29 (1.11, 1.49)b 1.02 (0.90, 1.15)
(2 years, referent)
Quartile post-dialysis body mass index
Quartile 1 (lowest) 8.25 (6.42, 10.60)b 1.73 (1.45, 2.07)b NS NS
Quartile 2 4.90 (3.91, 6.15)b 1.61 (1.37, 1.90)b
Quartile 3 2.44 (2.00, 2.98)b 1.45 (1.24, 1.70)b
(highest quartile, referent)
Vascular access
AV fistula or AV graft 1.80 (1.50, 2.16)b NE 1.27 (1.11, 1.46)b 1.50 (1.31, 1.71)b
(catheter, referent)
Mean dialysis session length minutes 1.024 (1.021, 1.027)b 1.004 (1.002, 1.006)b 1.004 (1.002, 1.006)b 0.995 (0.993, 0.997)b
Mean blood pump flow mL/minute 1.010 (1.008, 1.011)b 1.0045 (1.0036, 1.0054)b 1.001 (1.0004, 1.002)a NS
Increasing mean Kt/V NE 0.64 (0.51, 0.81)b NS NS
Increasing mean hemoglobin g/dL NS NS NE 1.28 (1.23, 1.34)b
Mean serum albumin 3.5/3.2 g/dL NS 1.41 (1.22, 1.63)b 2.53 (2.24, 2.87)b NE
Network (NW) NS NW 1 1.79 (1.29, 2.49)b NS NS
NW 2 1.81 (1.31, 2.50)b
NW 14 0.61 (0.44, 0.86)a
NW 16 1.66 (1.20, 2.29)a
NE is not entered into the model; NS is not statistically significant.
aP  0.01
bP  0.001
cP  0.05
The Network ranked 9th for each intermediate outcome was the referent Network. For arteriovenous (AV) fistula use, Network 9 was the referent.
Mutivariable analyses
After controlling for several patient characteristic and
clinical variables, Asian patients were twice as likely to
have a mean Kt/V1.2 as Caucasians, the referent group
[OR (95% CI) 2.10 (1.33, 3.32), P  0.01] (Table 3).
Asian patients were as likely to be dialyzed with an AV
fistula, to achieve a mean hemoglobin 11 g/dL, and to
have a mean serum albumin4.0/3.7 g/dL as Caucasians,
the referent group.
DISCUSSION
The Asian group is one of the fastest growing minority
groups in the United States, having increased by 48%
between 1990 and 2000, compared to a 13% increase in
the total population over the same time period [4]. To
describe and compare the dialysis experience and some
intermediate outcomes for Asian hemodialysis patients
to non-Asian hemodialysis patients, CMS’s ESRD CPM
Project included a nationally representative oversample
of Asian adult hemodialysis patients in the 2001 data
collection effort. In this study population, Asians were
as old and as likely to have diabetes as the etiology of
ESRD as compared to the Caucasian population, but
were older and more likely to be diabetic as compared to
the African American population. That diabetic ESRD is
more common among Asians is consistent with pre-
viously reported national statistics [5], confirming that
our sample population is representative of the national
ESRD population.
This study’s most important finding is that the Asian
American hemodialysis population enjoys similar if not
superior intermediate outcomes as compared to the Cau-
casian and African American populations. Asians had a
higher mean single-pool Kt/V as compared to both Cauca-
sian and African American patients and there were sig-
nificantly more Asians who had received the minimum
hemodialysis dose of Kt/V of 1.2 [12]. Furthermore,
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Asian patients were as likely as Caucasian patients and
more likely than African American patients to be dia-
lyzed with an AV fistula, to have achieved the minimum
recommended hemoglobin of 11 g/dL [13] and to have
obtained a nutritional outcome goal of a predialysis se-
rum albumin of 4.0 g/dL (BCG) [14]. Our finding that
Asian patients have a higher mean Kt/V is consistent with
a previous report that noted the mean Kt/V for Asians
was higher than for the Caucasian population [7]. Based
on an analysis of USRDS data from 1995 to 1997, the
mean Kt/V for Asians and Caucasians was 1.30 and 1.23,
respectively [15]. In our study, the superior delivered
dialysis for Asians persisted and the margin of difference
between Asians and Caucasians was even greater (mean
Kt/V of 1.62 versus 1.5, for Asians and Caucasians, respec-
tively). In our study, it was encouraging to note that across
the three racial populations studied, the mean Kt/V was
higher than the minimum recommended dialysis dose.
Notably, African Americans continued to have the low-
est mean Kt/V, consistent with previous reports [3].
The greater achieved dialysis dose among the Asian
patients may be partly explained by the smaller weight
and urea distribution volume observed in this popula-
tion, given that Kt/V is inversely related to body size
[16]. In our study, Asians were found to have a signifi-
cantly lower postdialysis BMI as compared to Caucasian
and African American patients, and patients with a low
BMI were more likely to have a mean Kt/V 1.2 (Table
3). However, on multivariable analysis, Asians were
found to have a twofold greater likelihood of achieving
a Kt/V 1.2, even after accounting for differences in
BMI. An alternative explanation may be the greater
percentage of Asians who receive dialysis through an
AV fistula and a greater percentage of African Ameri-
cans being dialyzed through a catheter, given that vascu-
lar access type is recognized to be predictive of dialysis
adequacy [17]. Primary AV fistulas are the preferred
access type because of the markedly lower complication
and thrombosis rate as compared to AV grafts and cuffed
dialysis catheters [18]. It is also possible that racial differ-
ences in compliance with treatment time may account
for variations in delivered dialysis therapy. African Amer-
icans have been found to have a higher likelihood of
skipping or shortening dialysis sessions as compared to
Caucasians [19]. Furthermore, this noncompliance to treat-
ment time was determined to be a significant predictor
of mortality [19]. Whether Asian Americans are less
likely to skip or shorten hemodialysis sessions has not
been studied. However, in an international comparison
of compliance rates, Japanese patients were significantly
less likely to skip dialysis treatments as compared to
American dialysis patients [20].
In this study, more Asians were dialyzed with an AV
fistula as compared to African Americans. Racial differ-
ences in vascular access persisted after accounting for
gender, age, diabetic ESRD, and body size. A plausible
explanation for this observation may be attributed to
differences in timing of referral to nephrologists. The
Choices for Healthy Outcomes in Caring for End-Stage
Renal Disease Center Study (CHOICE Study) demon-
strated that patients who were evaluated by a nephrolo-
gist four months prior to initiation of hemodialysis were
more likely to have an AV fistula as their initial form
of dialysis access [21]. However, an analysis of the USRDS
data demonstrated that Asians had an odds ratio of 1.7
for late initiation of dialysis, as defined by a glomerular
filtration rate (GFR) of 5 mL/min/1.73 m2, when com-
pared to Caucasian dialysis patients. As such, it is un-
likely that early nephrology consultation and placement
of AV fistula account for this finding. An alternative
explanation is that Asians possess biologic differences
compared to other racial groups that may account for a
lower tendency for the development of thrombosis, such
that the lifespan of created fistulas may be longer than
that observed in other racial groups. This may then ac-
count for a higher prevalence of this form of vascular
access among Asians. Reports about the prevalence of
postoperative pulmonary embolism in the Chinese popu-
lation cite a markedly lower rate of 2.6% [22] as com-
pared to 9.0% in Caucasians [23]. Furthermore, Asians
were found to have a lower rate of development of pe-
ripheral vascular disease as a complication of diabetes as
compared to Caucasians [24]. An alternative explanation
may be that Asians are overrepresented in ESRD Net-
works with clinicians who are more likely to practice
AV fistula creations. As revealed in our multivariable
analysis (Table 3), ESRD Network was a significant pre-
dictor for the insertion of AV fistulas. Furthermore, na-
tional statistics reveal that the proportion of Asians living
in regions designated as Networks 2 and 16 are greater
than those observed in other Networks [4].
In terms of anemia management, Asians achieved sim-
ilar hemoglobin levels compared to Caucasians, but re-
quired significantly higher intravenous erythropoietin
doses to maintain the same hemoglobin levels. The higher
dose was required despite better iron stores among Asian
patients. The reason for the apparent lower responsive-
ness of Asians to intravenous or subcutaneous erythro-
poietin is unknown. A possible reason may be related to
erythropoietin or erythropoietin receptor polymorphisms
across racial groups that may result in variations in re-
sponsiveness to erythropoietin. A recent report evaluat-
ing the genetic basis for gender differences in hematocrit
identified that polymorphisms in the erythropoietin re-
ceptor may contribute to the lower hematocrit among
females [25]. Whether similar polymorphisms in erythro-
poietin and its receptor may account for racial differences
in erythropoietin responsiveness needs further study.
Asian patients were found to have a higher mean se-
rum albumin as compared to Caucasian and African Amer-
ican patients. However, the Asian advantage did not
persist after accounting for age, diabetic ESRD, and use
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of an AV fistula. This suggests that the higher serum
albumin levels observed in the Asian population may be
accounted for by differences in demographic and clinical
characteristics of the Asian as compared to the Cauca-
sian and African American dialysis populations. Further-
more, the more common use of AV fistulas and conse-
quent improved delivered dialysis among Asians may
contribute to this finding.
The following limitations should be taken into account
in the interpretation of our findings. First, the term “Asian”
refers to an admixture of several races, including Orien-
tal (Chinese and Japanese), Indian, and Southeast Asian
races. Within the Asian race, marked genetic, clinical,
and behavioral differences exist. For instance, recent re-
ports suggest that renal disease risk factors vary signifi-
cantly among Asian subpopulations [26]. Thus, among
Asians, biologic differences are likely to exist that may
also translate to differences in ESRD intermediate out-
comes and long-term survival. Second, data on other rele-
vant hemodialysis intermediate outcomes were not avail-
able in this analysis. These include differences in calcium
and phosphate management, degree of control of hyper-
tension, presence of cardiovascular and other comorbid-
ity. Third, the slightly lower completion rate for Asian
patients’ forms compared to the overall sample (86% ver-
sus 95%) may have led to a selection bias, wherein Asian
patients with poorer outcomes were selectively excluded.
Furthermore, cultural and other behavioral characteris-
tics that may explain the improved intermediate out-
comes among Asians would need to be determined. In
so doing, differences that confer clinical advantage, in-
cluding diet, lifestyle, social support and degree of com-
pliance, may be better characterized and translated into
recommendations for disadvantaged dialysis popula-
tions. Finally, whether or not these observed racial differ-
ences in intermediate outcomes can account for differ-
ences in survival rates need further study. A goal of
the ESRD CPM Project is to determine if there is an
association between these intermediate outcomes and
subsequent morbidity and mortality.
CONCLUSION
Using a large nationally representative sample of
ESRD patients, we identified marked racial differences
in hemodialysis practices and intermediate outcomes. As
a whole, Asian American patients experienced similar,
if not superior, intermediate outcomes compared to Cau-
casian and African American patients. Whether these
differences can be accounted for by biologic or cultural
reasons need further study. Regardless of the underlying
reasons for the marked differences in intermediate out-
comes across racial groups, our findings suggest that indi-
vidualized dialysis prescriptions and monitoring of inter-
mediate outcomes needs to be further emphasized.
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